Pharmagreen Biotech Inc.

Pre-revenue cannabis/biotech micro-cap with a going-concern opinion, $8K cash and a recent Chapter 11 history.

Strengths

• Net loss narrowed year-over-year on derivative/penalty derecognition
• Some prepaid R&D and a nominal nutraceutical product launched

Risks

• Going concern: $8,016 cash, $1.7M working-capital deficit, $12.6M accumulated deficit, no revenue
• Reported ROE (88th pct) is a negative-equity artifact masking distress

Notable findings

• Going concernCapital Resources and Liquidity Our auditors have issued a “going concern” opinion, meaning that there is substantial doubt if we can continue as an on-going business unless we obtain additional ca